[1]
|
R. D. Wit, M. Aapro and P.R. Blower, “Is There a Phar-macological Basis for Differences in 5-HT3-Receptor Antagonist Efficacy in Refractory Patients?” Cancer Chemotherapy and Pharmacology, Vol. 56, No. 3, 2005, pp. 231-238. doi:10.1007/s00280-005-1033-0
|
[2]
|
M. Aapro and P. Blower, “5-Hydroxytryptamine Type-3 Receptor Antagonists for Chemotherapy-Induced and Radiotherapy-Induced Nausea and Emesis: Can We Safely Reduce the Dose of Administered Agents?” Cancer, Vol. 104, No. 1, 2005, pp. 1-13.
doi:10.1002/cncr.21141
|
[3]
|
J. T. Hickok, J. A. Roscoe, G. R. Morrow, C. W. Bole, H. W. Zhao, K. L. Hoelzer, S. R. Dakhil, T. Moore and T. R. Fitch, “5-Hydroxytryptamine-Receptor Antagonists versus Prochlorperazine for Control of Delayed Nausea Caused by Doxorubicin: A URCC CCOP Randomised Controlled Trial,” The Lancet Oncology, Vol. 6, No. 10, 2005, pp. 765-772. doi:10.1016/S1470-2045(05)70325-9
|
[4]
|
P. Eisenberg, J. F.Vadillo, R. Zamora, V. Charu, J. Haj-denberg, A. Cartmell, A. Macciocchi and S. Grunberg, “Improved Prevention of Moderately Emetogenic Che-motherapy-Induced Nausea and Vomiting with Palonose-tron, a Pharmacologically Novel 5-HT3 Receptor Anta-gonist. Results of a Phase III, Single-Dose Trial versus Dolasetron,” Cancer, Vol. 98, No. 11, 2003, pp. 2473- 2482. doi:10.1002/cncr.11817
|
[5]
|
http://www.rxlist.com/aloxi-drug.htm accessed January 2009.
|
[6]
|
M. Wang, X. Ding, H. Chen and X. Chen, “Enantiosepa-ration of Palonosetron Hydrochloride by Capillary Zone Electrophoresis with High-Concentration β-CD as Chiral Selector,” Analytical Sciences, Vol. 25, No. 10, 2009, pp. 1217-1220. doi:10.2116/analsci.25.1217
|
[7]
|
K. Tian, H. Chen, J. Tang, X. Chen and Z. Hu, “Enanti-oseparation of Palonosetron Hydrochloride by Micellar Electrokinetic Chromatography with Sodium Cholate as Chiral Selector,” Journal of Chromatography A, Vol. 1132, No. 325, 2006, pp. 333-336.
doi:10.1016/j.chroma.2006.08.090
|
[8]
|
P. Radhakrishnanand, D. V. Subba Rao and V. Himabin-du, “Validated Chiral LC Method for the Enantiomeric Separation of Palonosetron Hydrochloride,” Chromato-graphia, Vol. 69, No. 3-4, 2009, pp. 369-373.
doi:10.1365/s10337-008-0887-9
|
[9]
|
X.-R. Yu, M. Song and T.-J. Hang, “Direct Enantiomeric Separation of Palonosetron Hydrochloride by Chiral HPLC,” Chinese Journal of New Drugs, Vol. 10, 2008, p. 16.
|
[10]
|
J. W. Dolan, L. R. Snyder, N. M. Djordjevic, D. W. Hill and T. J. Waeghe, “Reversed-Phase Liquid Chromato-graphic Separation of Complex Samples by Optimizing Temperature and Gradient Time: I. Peak Capacity Limi-tations,” Journal of Chromatography A, Vol. 857, 1999, pp. 1-20. doi:10.1016/S0021-9673(99)00765-7
|
[11]
|
J. W. Dolan, L. R. Snyder, N. M. Djordjevic, D. W. Hill, D. L. Saunders, L. Van Heuhelem and T. J. Waeghe, “Simultaneous Variation of Temperature and Gradient Steepness for Reversed-Phase High-Performance Liquid Chromatography Method Development: I. Application to 14 Different Samples Using Computer Simulation,” Journal of Chromatography A, Vol. 803, 1998, pp. 1-31.
|
[12]
|
R. G. Wolcott, J. W. Dolan and L. R. Snyder, “Computer Simulation for the Convenient Optimization of Isocratic Reversed-Phase Liquid Chromatographic Separations by Varying Temperature and Mobile Phase Strength,” Jour-nal of Chromatography A, Vol. 869, No. 1-2, 2000, pp. 3-25. doi:10.1016/S0021-9673(99)00876-6
|
[13]
|
ICH, “Stability Testing of New Drug Substances and Products (Q1AR2),” ICH Harmonized Tripartite Guideline.
|